Skip to content

Released May 4, 2023, before the open

10-Q filed May 4, 2023, 34 days after period end · 0001171843-23-002868

Q1 2023 · 10-Q
Revenue—
Net Income-$7.84MN/M vs Q1 2022N/M vs Q4 2022
EPS, diluted—
Operating Income-$9,711,000N/M
Operating Cash Flow-$12,229,000N/M
Free Cash Flowderived-$12,229,000N/M

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2021Q1 2020
Net Income-$7.84M-$7.16M-$7.42M-$6.40M
EPS Diluted—-$0.07-$0.14-$0.90

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR